BofA raised the firm’s price target on Intra-Cellular (ITCI) to $118 from $100 and keeps a Buy rating on the shares after the company announced ...

BofA raised the firm’s price target on Intra-Cellular (ITCI) to $118 from $100 and keeps a Buy rating on the shares after the company announced a favorable Caplyta patent settlement with Sandoz ...

Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $132.00 target price (up previously from $108.00) on shares of Intra-Cellular Therapies in a research report on Wednesday.

On Monday, Mizuho (NYSE:MFG) Securities updated its financial outlook for Intra-Cellular Therapies (NASDAQ:ITCI), increasing the stock's price target from $100 to $140 while maintaining an Outperform ...

Observing a 9.56% increase, the current average has risen from the previous average price target of $99.33. Deciphering Analyst Ratings: An In-Depth Analysis The perception of Intra-Cellular ...

Intra-Cellular Therapies (NASDAQ:ITCI – Get Free Report) was upgraded by equities research analysts at Cantor Fitzgerald from ...

Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 6.53% of ...

Intra-Cellular Therapies Inc (ITCI) stock saw a modest uptick, ending the day at $126.5 which represents a slight increase of $0.30 or 0.24% from the prior close of $126.2. The stock opened at $126.64 ...

Intra-Cellular said last fall it was expanding its sales force to target growth opportunities with primary care doctors. The company also is seeking U.S. Food and Drug Administration approval to ...